Boehringer Ingelheim Limited Archives | Page 3 of 3

Home / Posts tagged Boehringer Ingelheim Limited (Page 3)

Breaking new ground in mental health research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience launch first of its kind study investigating the day-to-day experience of patients with psychiatric disorders

Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 (Korea Bizwire) – Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric disorders, and how these experiences relate to their brain activity. The first-of-its-kind study will use novel technology to quantify brain activity, mood, and behavior at home in people who have been diagnosed [...]

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 (Korea Bizwire) New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of Medicine Data presented included an objective response rate (ORR) of 71%, with 7% of patients achieving complete responses (CR), and a 96% disease [...]

New survey shows that over 90% of animal owners trust and appreciate veterinary teams but underestimate the demands of the profession

New survey data show 94% of animal owners appreciate the work of veterinarians1, compared to only 49% of veterinary professionals feeling their profession is appreciated, among other findings.2 The survey confirms differences in perspectives: 65% of animal owners think veterinarians have a good work-life balance1 while 48% of veterinarians say animal owners underappreciate the way they [...]

Boehringer Ingelheim announces succession Chairmen Shareholders’ Committee and Board of Managing Directors

Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of Managing Directors, to succeed Hubertus von Baumbach as Chairman of the Board of Managing Directors Appointments to be effective July 1, 2025 The Shareholders’ Committee of Boehringer Ingelheim have announced the following appointments in the Shareholders’ Committee and [...]

Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches

Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. [...]

Boehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically significant effects on cognition or functioning were observed in patients treated with iclepertin versus placebo at six months.1 All three trials demonstrated that iclepertin, a [...]